Verdiva Bio

Verdiva Bio is a well-funded private biotech targeting the massive obesity and cardiometabolic market with a differentiated pipeline of peptide-based therapies. Its lead asset, VRB-101, is an oral, once-weekly GLP-1 analog (ecnoglutide) currently in Phase 2b development, supported by a proprietary oral absorption enhancer. The company is also developing amylin-based candidates and combinations, positioning itself in the next wave of incretin/amylin therapies with a focus on oral and convenient dosing. Backed by over $410M in Series A financing and a seasoned leadership team, Verdiva aims to become a key player in the evolving metabolic disease landscape.

Rational engineering of peptide analogs (e.g., cAMP-biased GLP-1) combined with a proprietary oral absorption enhancer (T2026) to enable once-weekly oral dosing of peptide therapeutics.

Verdiva competes in the highly competitive obesity therapeutics market against dominant injectable GLP-1s (e.g., semaglutide, tirzepatide) and a pipeline of next-generation injectable multi-agonists. Its primary differentiation is focused on oral, once-weekly dosing, competing with other oral GLP-1 candidates in development (e.g., from Novo Nordisk, Pfizer).